ATLANTA, Dec. 4 /PRNewswire-FirstCall/ -- Eclipsys Corporation(R) , The Outcomes Company(R), today announced Bob Elson, MD, Eclipsys' chief medical officer, will present on the value of e-Prescribing during a Steering Committee Lunch Session on Capitol Hill. The session, entitled "IT for On-Line Diagnostics, e-Prescribing & Bioinformatics," is designed to help policy-makers as they consider all of the many issues and opportunities facing the implementation of e-Prescribing and adoption of bioinformatics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO )

"We are excited that our chief medical officer is being recognized for his expertise on such an important topic as e-Prescribing and asked to play a role in shaping future legislation," said Jay Deady, Eclipsys executive vice president. "Eclipsys is committed to providing solutions that help care providers improve patient safety, and e-Prescribing can be critical to helping reduce avoidable medication errors. Dr. Elson has played a vital role in helping us bring to market the powerful capabilities of our e-Prescribing solution, which provides expert clinical decision support at the point of care for safe, informed prescribing. The solution also cross-references drug therapies with patient drug and medical histories, medical knowledge databases and payor formularies."

Participating with Elson on the program are Jonathan White, MD, health IT portfolio manager, Agency for Healthcare Research and Quality (AHRQ); Jake Jennings, associate chief, Wireline Services Bureau, Federal Communications Commission (FCC); Harry Reynolds, vice president, Blue Cross Blue Shield of North Carolina; John Carroll, Association of Public Health Laboratories (APHL); and Stephen Badger, chief executive officer, George Washington University Medical Faculty Associates.

The session will take place on Wednesday, December 5, from 12:00 to 2:00 p.m. in Room SR 188 of the Russell Senate Office Building at the United States Capitol.

As Eclipsys chief medical officer, Dr. Elson works with Eclipsys senior executives to set the company's long-term clinical strategy and short-term priorities for Eclipsys solutions. Dr. Elson has extensive experience with e-Prescribing. In addition to designing and managing one of the first commercial e-Prescribing applications, he spent two years as the medical director at RxHub, a vendor-neutral data exchange utility that has figured prominently in the e-Prescribing landscape. Most recently, Dr. Elson directed the Cleveland CMS e-Prescribing pilot, a year-long project designed to characterize e-Prescribing adoption and workflow in small physician practices, as well as test e-Prescribing transactions being considered for inclusion in the final Medicare e-Prescribing rules. Dr. Elson was a major contributing author to the eHealth Initiative's landmark e-Prescribing Report in 2004. Dr. Elson, a former National Library of Medicine Fellow in Informatics, has a strong academic background and remains on the research faculty at the MetroHealth Center for Healthcare Policy and Research in Cleveland.

About the Steering Committee on Telehealth and Healthcare Informatics

The Capitol Hill "Steering Committee on Telehealth and Healthcare Informatics" is in its 15th year of educational sessions, technology demonstrations, and special programs to help advance a public and private sector understanding of issues facing the implementation of information technologies for healthcare. The programs are widely attended, publicly available educational lunch sessions building on in-depth program content of more than 100 past programs. The agenda continues to focus on working with a wide variety of groups (academic, government, and the private sector) to help develop legislative priorities and awareness related to Telehealth, eHealth and health care informatics. The Capitol Hill Steering Committee programs are open to the public at no charge; however, attendees do need to register by emailing RSVP@hlthtech.com.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client satisfaction outcomes. For more information, see http://www.eclipsys.com/ or email info@eclipsys.com.

Management's prepared remarks and answers to questions during the presentation referenced in this release may include forward-looking statements, including concerning the company's sales, marketing and operational initiatives, future financial results, operating performance, development efforts, and the benefits provided by Eclipsys software and services. Actual results may differ from those projected due to a variety of risks and uncertainties. Future performance expectations are predicated upon achievement of various sales and performance targets that may be difficult to meet. Sales may be slower than expected due to market conditions, competition, and other factors. Costs may be greater than anticipated due to the potential need to increase spending to ensure performance in accordance with commitments to clients and other factors. Software development may take longer and cost more than expected, and incorporation of anticipated features and functionality may be delayed, due to various factors including programming and integration challenges and resource constraints. The market is highly competitive. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client's circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, implementation or consulting services. The success and timeliness of the company's services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and clients can terminate contracts, assess penalties or reduce contract scope under certain circumstances. More information about company risks is available in recent Form 10-K and other filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation.

Eclipsys Jason Cigarran Robert J. Colletti Director, Media Relations Chief Financial Officer (investors) (561) 322-4355 (561) 322-4655 jason.cigarran@eclipsys.cominvestor.relations@eclipsys.com

CONTACT: Media, Jason Cigarran, Director, Media Relations,
+1-561-322-4355, jason.cigarran@eclipsys.com; Investors, Robert J. Colletti,
Chief Financial Officer, +1-561-322-4655, investor.relations@eclipsys.com,
both of Eclipsys Corporation

Web site: http://www.eclipsys.com/